Skip to main content

Company News

March 26, 2024

Precision matters: Navigating the landscape of quality control in biologics

Humans have been using plant and animal derived products (biologics) to treat disease for thousands of years, but the advent of mass production in the 20th century enabled the growth of biologics as a recognized class of medicines. Unlike chemically derived medicines, which combine specific ingredients in an ordered process, biologics are typically very large, complex molecules or mixtures of molecules that are difficult to characterize.
  • January 04, 2023

    bioMérieux establishes Antimicrobial Stewardship Centers of Excellence 

    bioMérieux takes a proactive, partnership-driven approach to combating AMR with diagnostic and data-driven solutions to improve stewardship efforts. To further this goal, bioMérieux created the AMS Centers of Excellence (CoE) designation awarded to hospitals around the world as a sign of a joint commitment to best AMS practices.
  • December 08, 2022

    Cell and Gene Therapies: bioMérieux partners with NecstGen

    bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.
  • October 27, 2022

    20 years of collaboration in the fight against infectious diseases.

    For 20 years, bioMérieux and the Hospices Civils de Lyon (HCL) have been collaborating in an innovative public/private research partnership. Joined in 2016 by Claude Bernard Lyon 1 University, the three institutions are working to figure out the mechanisms of immunity in order to develop diagnostic tests.

Follow us on Socials for more news!